Vutiglabridin improves neurodegeneration in MPTP-induced Parkinson's disease mice by targeting mitochondrial paraoxonase-2
Sora Kang, Leo Sungwong Choi, Suyeol Im, Ji Hwan Kim, Keun Woo Lee, Dong Hwan Kim, Jung Hee Park, Min‐Ho Park, Jaemin Lee, Sun Kyung Park, Kwang Pyo Kim, Hyeong Min Lee, Hyun Ju Jeon, Hyung Soon Park, Sang‐Ku Yoo, Youngmi Kim Pak
Vutiglabridin, a clinical-stage drug for obesity, shows neuroprotective effects in Parkinson's disease models by targeting mitochondrial PON2.
bioRxiv · Oct 20, 2022 · PreprintNeuroscience